Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists
First Claim
Patent Images
1. A peptidic compound of formula (I):
-
R1—
Z—
R2
(I)or a salt or solvate thereof,wherein Z is a peptide moiety of formula (II);
Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Ile-Gln-X14-X15-Lys-Arg-Ala-Ala-Aib-Glu- Phe-Ile-Glu-Trp-Leu-Lys-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-X40
(II)wherein;
X14 is an amino acid residue selected from Met, Leu, and Nle,X15 is an amino acid residue selected from Glu and Asp,X40 is absent or is Lys,R1 is NH2, andR2 is OH or NH2.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
636 Citations
23 Claims
-
1. A peptidic compound of formula (I):
-
R1—
Z—
R2
(I)or a salt or solvate thereof, wherein Z is a peptide moiety of formula (II);
Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Ile-Gln-X14-X15-Lys-Arg-Ala-Ala-Aib-Glu- Phe-Ile-Glu-Trp-Leu-Lys-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-X40
(II)wherein; X14 is an amino acid residue selected from Met, Leu, and Nle, X15 is an amino acid residue selected from Glu and Asp, X40 is absent or is Lys, R1 is NH2, and R2 is OH or NH2. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)
-
Specification